There is also a pressing need to better understand the extent to which α-synuclein aggregates in neurometabolic diseases recapitulate key pathogenic features of Lewy body diseases, such as increased levels of phosphorylation at serine 129 and the ability to seed aggregation of monomeric α-synuclein. This evidence concerns the gene SNCA and Lewy body dementia.